// App-Quantinova.ai

544 : Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study

Researchers

Presenter

  • Atul Deodhar

Principal Investigators

  • Désirée van der Heijde

  • Lianne Gensler

  • Huji Xu

  • Karl Gaffney

  • Hiroaki Dobashi

  • Walter P Maksymowych

  • Martin Rudwaleit

  • Marina Magrey

  • Dirk Elewaut

  • Marga Oortgiesen

  • Carmen Fleurinck

  • Natasha de Peyrecave

  • Alicia Ellis

  • Thomas Vaux

  • Julie Shepherd-Smith

  • Xenofon Baraliakos

Medical Centers

  • Oregon Health & Science University, Portland, OR, USA, Portland, OR

  • Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands

  • Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Franciso, California, United States

  • Department of Hematology, Shanghai Changhai Hospital Affiliated to The 2nd Military Medical University, Shanghai, China

  • Norfolk and Norwich University Hospitals NHS Trust, Norwich, United Kingdom.

  • Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Kagawa, Japan

  • Department of Surgery, University of Alberta, Edmonton, AB, Canada

  • University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium

  • Case Western Reserve University and University Hospitals, Cleveland, OH

  • Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium

  • UCB Pharma, Raleigh, NC

  • UCB Pharma, Brussels, Belgium, Oosterzele, Belgium

  • UCB Pharma, Brussels, Belgium

  • UCB Pharma, Raleigh, NC

  • UCB Pharma, Slough, UK Slough United Kingdom

  • Rheumazentrum Ruhrgebiet, Herne, Germany

Locations

  • United States

  • Netherlands

  • China

  • United Kingdom

  • Japan

  • Canada

  • Belgium

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Non-radiographic axial spondyloarthritis

  • Sacroiliitis

Biomarkers

  • C reactive protein

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT03928704

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved